Shardul Amarchand Mangaldas & Co (SAM) advised Morgan Stanley PE on the sale of 2,500,000 equity shares (representing approximately 2.46% of the paid-up share capital) of Sahajanand Medical Technologies Limited (“Issuer”) which comprised (a) sale of 1,335,178 Equity Shares (approx. 1.31%, ₹45.93 crore) through an offer for sale in the initial public offering of the Issuer aggregating to ₹475.48 crore (approx. US$55.23 million) (“Offer”), and (b) secondary transfer of 1,164,822 Equity Shares (approx. 1.15%, ₹40.06 crore) prior to the Offer. The equity shares of the Issuer listed on BSE and NSE on October 23, 2026.
The book running lead managers for the Offer were Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited and Nuvama Wealth Management Limited.
Sahajanand Medical Technologies is one of the few listed medical devices companies and has a presence across 65 countries.
The SAM team comprised Nikhil Naredi (Partner), Chinmay Sethia (Principal Associate) and Shariba Tasneem (Associate) on capital markets, and Nivedita Tiwari (Partner), Kuhuk Jain (Principal Associate) and Jasmine Khan (Senior Associate) on general corporate advisory.
